Statement 1 Adults with a baseline total cholesterol above 7.5 mmol/l are assessed for a clinical diagnosis of familial hypercholesterolaemia (FH).
Statement 2 People with a clinical diagnosis of FH are referred for specialist assessment.
Statement 3 People with a clinical diagnosis of FH are offered DNA testing as part of a specialist assessment.
Statement 4 Children at risk of FH are offered diagnostic tests by the age of 10 years.
Statement 5 Relatives of people with a confirmed diagnosis of monogenic FH are offered DNA testing through a nationwide, systematic cascade process.
Statement 6 Adults with FH receive lipid‑modifying drug treatment to reduce LDL‑C concentration by more than 50% from baseline.
Statement 7 Children with FH are assessed for lipid‑modifying drug treatment by a specialist with expertise in FH in a child‑focused setting by the age of 10 years.
Statement 8 People with FH are offered a structured review at least annually.